2. Tandogdu Z., Wagenlehner F.M.E. Global Epidemiology of Urinary Tract Infections. Curr. Opin. Infect. Dis. 2016;29(1):73–79. Doi: 10.1097/qco.0000000000000228.

3. Epp A. Larochelle AUrogynaecology Committee Family Physicians Advisory Committee. . Recurrent urinary tract infection J Obstet Gynaecol Can. 2010;32:1082–1090.

4. Foxman B. Recurring urinary tract infection: Incidence and risk factors Am J Public Health. 1990;80:331–333.

5. Ikäheimo R., Siitonen A., Heiskanen T., Kärkkäinen U., Kuosmanen P., Lipponen P., et al. Recurrence of urinary tract infection in a primary care setting: Analysis of a 1-year follow-up of 179 women Clin Infect Dis. 1996;22:91–99.

6. Renard J., Ballarini S., Mascarenhas T., Zahran M., Quimper E., Choucair J. et al. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: A prospective, observational study Infect Dis Ther. 2014;4:125–135.

7. Ciani O., Grassi D., Tarricone R. An economic perspective on urinary tract infection: The “costs of resignation” Clin Drug Investig. 2013;33:255–261.

8. Wein A.J., Rovner E.S. Definition and Epidemiology of Overactive Bladder. Urology. 2002;60(5 Suppl. 1):7–12. discussion 12. Doi: 10.1016/s0090-4295(02)01784-3.

9. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn. 2002;21:167–178.

10. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How Widespread Are the Symptoms of an Overactive Bladder and How Are They Managed? A Population-Based Prevalence Study. BJU Int. 2021;87(9):760–766. Doi: 10.1046/j.1464-410x.2001.02228.x.

11. Kinsey D., Pretorius S., Glover L., Alexander T. The Psychological Impact of Overactive Bladder: A Systematic Review. J. Health Psychol. 2016;21(1):69–81. Doi: 10.1177/1359105314522084.

12. Coyne K.S., Sexton C.C., Kopp Z.S., Ebel-Bitoun C., Milsom I., Chapple C. The Impact of Overactive Bladder on Mental Health, Work Productivity and Health-Related Quality of Life in the UK and Sweden: Results from EpiLUTS. BJU Int. 2021;108(9):1459–1471. Doi: 10.1111/j.1464-410x.2010.10013.x.

13. Wagg A., Compion G., Fahey A., Siddiqui E. Persistence with Prescribed Antimuscarinic Therapy for Overactive Bladder: a UK Experience. BJU Int. 2012;110(11):1767–1774. Doi: 10.1111/j.1464-410x.2012.11023.x.

14. Kim T.H., Lee K.-S. Persistence and Compliance with Medication Management in the Treatment of Overactive Bladder. Investig. Clin. Urol. 2016;57(2):84–93. Doi: 10.4111/icu.2016.57.2.84.

15. Yeowell G., Smith P., Nazir J., Hakimi Z., Siddiqui E., Fatoye F. Real-world Persistence and Adherence to Oral Antimuscarinics and Mirabegron in Patients with Overactive Bladder (OAB): a Systematic Literature Review. BMJ Open. 2018;8(11):e021889. Doi: 10.1136/bmjopen-2018-021889.

16. Schurch B., de Sèze M., Denys P., Chartier-kastler E., Haab F., Everaert K. et al. Botulinum Toxin Type a Is a Safe and Effective Treatment for Neurogenic Urinary Incontinence: Results of a Single Treatment, Randomized, Placebo Controlled 6-month Study. J Urology. 2005;174(1):196–200. Doi: 10.1097/01.ju.0000162035.73977.1c .

17. Apostolidis A., Dasgupta P., Denys P., Elneil S., Fowler C.J., Giannantoni A. et al. Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: a European Consensus Report. Eur. Urol. 2009;55(1):100–120. Doi: 10.1016/j.eururo.2008.09.009.

18. Chen J.L., Kuo H.C. Clinical Application of Intravesical Botulinum Toxin Type A for Overactive Bladder and Interstitial Cystitis. Investig. Clin. Urol. 2020;61(Suppl. 1):S33–S42. Doi: 10.4111/icu.2020.61.S1.S33.

19. Khasriya R.K., Brackenridge A., Horsley L., Sathiananthamoorthy H., Malone-Lee S.J. The Antibiotic Treatment of OAB Cohort. 36th Annual IUGA Meeting, Lisbon, Portugal, 28 June–2 July 2011. Int. Urogynecology J. 2011;22(1):1–195.

20. Vijaya G., Puccini F., Dutta S., Singh A., Bray R., Digesu A., et al. 38th Annual IUGA Meeting, Dublin, Ireland, 28 May–1 June 2013: Oral Presentations. Int. Urogynecology J. 2013;24(1):79.

21. Ke Qian-Sheng, Lee Cheng-Ling, Kuo Hann-Chorng. Recurrent urinary tract infection in women and overactive bladder – Is there a relationship? Tzu Chi Medical Journal. 2020;33(1):13–21. Doi: 10.4103/tcmj.tcmj_38_20.

22. Shie J.H., Kuo H.C. Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome. Tzu Chi Med J. 2012;24:170–177.

23. Chuang F.C., Kuo H.C. Increased urothelial cell apoptosis and chronic inflammation are associated with recurrent urinary tract infection in women. PLoS One. 2013;8:e63760.

24. Tyagi P., Barclay D., Zamora R., Yoshimura N., Peters K., Vodovotz Y., et al. Urine cytokines suggest an inflammatory response in the overactive bladder: A pilot study Int Urol Nephrol. 2010;42:629–635.

25. Chung S.D., Liu H.T., Lin H., Kuo H.C. Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder Neurourol Urodyn. 2011;30:417–420.

26. Tomas M.E., Getman D., Donskey C.J., Hecker M.T. Overdiagnosis of urinary tract infection and underdiagnosis of sexually transmitted infection in adult women presenting to an emergency department J Clin Microbiol. 2015;53:2686–2692.

27. Khan Z., Healey G.D., Paravati R., Berry N., Rees E., Margarit L. et al. Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study. Front. Cell. Infect. Microbiol. 2021;11, 752275. Doi: 10.3389/fcimb.2021.752275.

28. Khasriya R., Khan S., Lunawat R., Bishara S., Bignal J., Malone-Lee M., et al. The Inadequacy of Urinary Dipstick and Microscopy as Surrogate Markers of Urinary Tract Infection in Urological Outpatients with Lower Urinary Tract Symptoms without Acute Frequency and Dysuria. J Urology. 2010;183(5):1843–1847. Doi: 10.1016/j.juro.2010.01.008.

29. Rosen D.A., Hooton T.M., Stamm W.E., Humphrey P.A., Hultgren S.J. Detection of Intracellular Bacterial Communities in Human Urinary Tract Infection. PLoS Med. 2007;4(12):e329. Doi: 10.1371/journal.pmed.0040329.

30. Vijaya G., Cartwright R., Derpapas A., Gallo P., Fernando R., Khullar V. Changes in Nerve Growth Factor Level and Symptom Severity Following Antibiotic Treatment for Refractory Overactive Bladder. Int. Urogynecol J. 2013;24(9):1523–1528. Doi: 10.1007/s00192-012-2038-y.

31. Khasriya R., Sathiananthamoorthy S., Ismail S., Kelsey M., Wilson M., Rohn J.L. et al. Spectrum of Bacterial Colonization Associated with Urothelial Cells from Patients with Chronic Lower Urinary Tract Symptoms. J. Clin. Microbiol. 2013;51(7):2054–2062. Doi: 10.1128/jcm.03314-12.

32. Cheng Y., Chen Z., Gawthorne J. A., Mukerjee C., Varettas K., Mansfield K. J., et al. Detection of Intracellular Bacteria in Exfoliated Urothelial Cells from Women with Urge Incontinence. Pathog. Dis. 2016;74(7). ftw067. Doi: 10.1093/femspd/ftw067.

33. Gill K., Kang R., Sathiananthamoorthy S., Khasriya R., Malone-Lee J. A Blinded Observational Cohort Study of the Microbiological Ecology Associated with Pyuria and Overactive Bladder Symptoms. Int. Urogynecol J. 2018;29(10):1493–1500. Doi: 10.1007/s00192-018-3558-x.

34. Justice S.S., Hunstad D.A., Seed P.C., Hultgren S.J. Filamentation by Escherichia coli Subverts Innate Defenses during Urinary Tract Infection. Proc. Natl. Acad. Sci. U.S.A. 2006;103(52):19884–19889. Doi: 10.1073/pnas.0606329104.

35. Ognenovska S., Chen Z., Mukerjee C., Moore K.H., Mansfield K.J. Bacterial Colonization of Bladder Urothelial Cells in Women with Refractory Detrusor Overactivity: the Effects of Antibiotic Therapy. Pathog. Dis. 2021;79(6): ftab031. Doi: 10.1093/femspd/ftab031.

36. Gill K., Horsley H., Swamy S., Khasriya R., Malone-Lee J. A Prospective Observational Study of Urinary Cytokines and Inflammatory Response in Patients with Overactive Bladder Syndrome. BMC Urol. 2021;21(1):39. Doi: 10.1186/s12894-021-00809-4.

37. Contreras-Sanz A., Krska L., Balachandran A.A., Curtiss N.L., Khasriya R., Kelley S., et al. Altered Urothelial ATP Signaling in a Major Subset of Human Overactive Bladder Patients with Pyuria. Am. J. Physiology-Renal Physiology. 2016;311(4):F805–F816. Doi: 10.1152/ajprenal.00339.2015.

38. Hainau B., Dombernowsky P. Histology and cell proliferation in human bladder tumors.An autoradiographic study. Cancer. 1974;33:115–126.

39. Gandhi D., Molotkov A., Batourina E., Schneider K., Dan H., Reiley M., et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium Dev Cell. 2013;26:469–482.

40. Mysorekar I.U., Isaacson-Schmid M., Walker J.N., Mills J.C., Hultgren S.J. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection Cell Host Microbe. 2009;5:463–475.

41. Shin K., Lee J., Guo N., Kim J., Lim A., Qu L. et al Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472:110–114.

42. Graham E., Chai T.C. Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis Curr Urol Rep. 2006;7:440–446.

43. Tomaszewski J.E., Landis J.R., Russack V., Williams T.M., Wang L.P., Hardy C., et al. Biopsy features are associated with primary symptoms in interstitial cystitis: Results from the interstitial cystitis database study Urology. 2001;57:67–81.

44. Liu H.T., Jiang Y.H., Kuo H.C. Alteration of urothelial inflammation, apoptosis, and junction protein in patients with various bladder conditions and storage bladder symptoms suggest common pathway involved in underlying pathophysiology Low Urin Tract Symptoms. 2015;7:102–107.

45. Rodhe N., Löfgren S., Strindhall J., Matussek A., Mölstad S. Cytokines in Urine in Elderly Subjects with Acute Cystitis and Asymptomatic Bacteriuria. Scand. J. Prim. Health Care. 2009;27 (2):74–79. Doi: 10.1080/02813430902757634.

46. Armbruster C.E., Smith S.N., Mody L., Mobley H.L.T.. Urine Cytokine and Chemokine Levels Predict Urinary Tract Infection Severity Independent of Uropathogen, Urine Bacterial Burden, Host Genetics, and Host Age. Infect. Immun. 2018;86(9):e00327. Doi: 10.1128/IAI.00327-18.

47. Davidoff R., Yamaguchi R., Leach G.E., Park E., Lad P.M. Multiple Urinary Cytokine Levels of Bacterial Cystitis. J. Urology. 1997;157(5):1980–1985. Doi: 10.1097/00005392-199705000-00125.

48. Sundac L., Dando S.J., Sullivan M.J., Derrington P., Gerrard J., Ulett G.C. Protein-based Profiling of the Immune Response to Uropathogenic Escherichia coli in Adult Patients Immediately Following Hospital Admission for Acute Cystitis. Pathog. Dis. 2016;74(6):ftw062. Doi: 10.1093/femspd/ftw062.

49. Tyagi P., Barclay D., Zamora R., Yoshimura N., Peters K., Vodovotz Y., et al. Urine Cytokines Suggest an Inflammatory Response in the Overactive Bladder: a Pilot Study. Int. Urol. Nephrol. 2010;42(3):629–635. Doi: 10.1007/s11255-009-9647-5.

50. Hannan T.J., Roberts P.L., Riehl T.E., van der Post S., Binkley J.M., Schwartz D.J. et al. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine. 2014;1(1):46–57. Doi: 10.1016/j.ebiom.2014.10.011.

51. Tyagi P., Tyagi V., Qu X., Chuang Y. C., Kuo H.-C., Chancellor M. Elevated CXC Chemokines in Urine Noninvasively Discriminate OAB from UTI. Am. J. Physiology-Renal Physiology. 2016;311(3):F548–F554. Doi: 10.1152/ajprenal.00213.2016.

52. Ghoniem G., Faruqui N., Elmissiry M., Mahdy A., Abdelwahab H., Oommen M., et al. Differential Profile Analysis of Urinary Cytokines in Patients with Overactive Bladder. Int. Urogynecol J. 2011;22(8):953–961. Doi: 10.1007/s00192-011-1401-8.

53. Tyagi P., Tyagi V., Qu X., Lin H.-T., Kuo H.-C., Chuang Y.-C., et al.. Association of Inflammaging (Inflammation + Aging) with Higher Prevalence of OAB in Elderly Population. Int. Urol. Nephrol. 2014;46(5):871–877. Doi: 10.1007/s11255-013-0621-x.

54. Ma E., Vetter J., Bliss L., Lai H.H., Mysorekar I.U., Jain S.A. Multiplexed Analysis Approach Identifies New Association of Inflammatory Proteins in Patients with Overactive Bladder. Am. J. Physiology-Renal Physiology. 2016;311(1):F28–F34. Doi: 10.1152/ajprenal.00580.2015.

55. Alkis O., Zumrutbas A. E., Toktas C., Aybek H., Aybek Z. The Use of Biomarkers in the Diagnosis and Treatment of Overactive Bladder: Can We Predict the Patients Who Will Be Resistant to Treatment? Neurourol. Urodynam. 2017;36(2):390–393. Doi: 10.1002/nau.22939.

56. Pillalamarri N., Shalom D.F., Pilkinton M.L., Winkler H.A., Chatterjee P.K., Solanki M., et al. Inflammatory Urinary Cytokine Expression and Quality of Life in Patients with Overactive Bladder. Female Pelvic Med. Reconstr. Surg. 2018;24(6):449–453. Doi: 10.1097/spv.0000000000000492.

57. Chiu I.M., Heesters B.A., Ghasemlou N., Von Hehn C.A., Zhao F., Tran J., et al. Bacteria Activate Sensory Neurons that Modulate Pain and Inflammation. Nature. 2013;501(7465):52–57. Doi: 10.1038/nature12479.

58. Yang N.J., Chiu I.M. Bacterial Signaling to the Nervous System through Toxins and Metabolites. J. Mol. Biol. 2017;429(5):587–605. Doi: 10.1016/j.jmb.2016.12.023.

59. Blake K.J., Baral P., Voisin T., Lubkin A., Pinho-Ribeiro F.A., Adams K.L., et al. Staphylococcus aureus Produces Pain through Pore-Forming Toxins and Neuronal TRPV1 that Is Silenced by QX-314. Nat. Commun. 2018;9(1):37. Doi: 10.1038/s41467-017-02448-6.

60. Uhlig F., Grundy L., Garcia-Caraballo S., Brierley S.M., Foster S.J., Grundy D. Identification of a Quorum Sensing-dependent Communication Pathway Mediating Bacteria-Gut-Brain Cross Talk. Science. 2020;23(11):101695. Doi: 10.1016/j.isci.2020.101695.

61. de Groat W.C., Yoshimura N. Afferent Nerve Regulation of Bladder Function in Health and Disease. Handb. Exp. Pharmacol. 2009;194:91–138. Doi: 10.1007/978-3-540-79090-7_4.

62. Grundy L., Caldwell A., Garcia Caraballo S., Erickson A., Schober G., Castro J., et al. Histamine Induces Peripheral and Central Hypersensitivity to Bladder Distension via the Histamine H1 Receptor and TRPV1. Am. J. Physiology-Renal Physiology. 2020;318(2):F298–f314. Doi: 10.1152/ajprenal.00435.2019.

63. Smith Y.C., Rasmussen S.B., Grande K.K., Conran R.M., O’Brien A.D. Hemolysin of Uropathogenic Escherichia coli Evokes Extensive Shedding of the Uroepithelium and Hemorrhage in Bladder Tissue within the First 24 hours after Intraurethral Inoculation of Mice. Infect. Immun. 2008;76(7):2978–2990. Doi: 10.1128/iai.00075-08.

64. Thumbikat P., Berry R.E., Zhou G., Billips B.K., Yaggie R.E., Zaichuk T., et al. Bacteria-induced Uroplakin Signaling Mediates Bladder Response to Infection. PLoS Pathog. 2009;5(5):e1000415. Doi: 10.1371/journal.ppat.1000415.

65. Wood M.W., Breitschwerdt E.B., Nordone S.K., Linder K.E., Gookin J.L. Uropathogenic E. coli Promote a Paracellular Urothelial Barrier Defect Characterized by Altered Tight Junction Integrity, Epithelial Cell Sloughing and Cytokine Release. J. Comp. pathology. 2012;147(1):11–19. Doi: 10.1016/j.jcpa.2011.09.005.

66. Grundy L., Caldwell A., Lumsden A., Mohammadi E., Hannig G., Greenwood Van-Meervald B., et al. Experimentally Induced Bladder Permeability Evokes Bladder Afferent Hypersensitivity in the Absence of Inflammation. Front. Neurosci. 2020;14:590871. Doi: 10.3389/fnins.2020.590871.

67. Grundy L., Caldwell A., Brierley S.M. Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome. Front. Neurosci. 2018;12:931. Doi: 10.3389/fnins.2018.00931.

68. Brierley S.M., Goh K.G.K., Sullivan M.J., Moore K.H., Ulett G.C., Grundy L. Innate Immune Response to Bacterial Urinary Tract Infection Sensitises High-Threshold Bladder Afferents and Recruits Silent Nociceptors. Pain. 2020;161(1):202–210. Doi: 10.1097/j.pain.0000000000001692.

69. Grundy L., Andrea M.H., Ashlee C., Joel C., Vasiliki S., Vladimir P.Z., et al. Translating Peripheral Bladder Afferent Mechanosensitivity to Neuronal Activation within the Lumbosacral Spinal Cord of Mice. Pain. 2018;160(4):793–804. Doi: 10.1097/j.pain.0000000000001453.

70. Geppetti P., Nassini R., Materazzi S., Benemei S. The Concept of Neurogenic Inflammation. BJU Int. 2008;101(Suppl. 3):2–6. Doi: 10.1111/j.1464-410X.2008.07493.x.

71. Balachandran A.A., Wildman S.S., Strutt M., Duckett J. Is chronic urinary infection a cause of overactive bladder? Eur J Obstet Gynecol Reprod Biol. 2016;201:108–112.

72. Drake M.J., Morris N., Apostolidis A., Rahnama’i M.S., Marchesi J.R. The urinary microbiome and its contribution to lower urinary tract symptoms; ICI-RS 2015 Neurourol Urodyn. 2017;36:850–853.

73. Govender Y., Gabriel I., Minassian V., Fichorova R. The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women Front Cell Infect Microbiol. 2019;9:133.

74. Thomas-White K.J., Hilt E.E., Fok C., Pearce M.M., Mueller E.R., Kliethermes S., et al. Incontinence medication response relates to the female urinary microbiota Int Urogynecol J. 2016;27:723–733.

75. Abbasian B., Shair A., O’Gorman D.B., Pena-Diaz A.M., Brennan L., Engelbrecht K., et al. Potential role of extracellular ATP released by bacteria in bladder infection and contractility mSphere. 2019;4:e00439–419.

76. Chen Z., Phan M.D., Bates L.J., Peters K.M., Mukerjee C., Moore K.H., et al. The urinary microbiome in patients with refractory urge incontinence and recurrent urinary tract infection Int Urogynecol J. 2018;29:1775–1782.

77. Martinez J.J., Mulvey M.A., Schilling J.D., Pinkner J.S., Hultgren S.J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells EMBO J. 2000;19:2803–2812.

78. Mulvey M.A., Schilling J.D., Hultgren S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection Infect Immun. 2001;69:4572–4579.

79. Justice S.S., Hung C., Theriot J.A., Fletcher D.A., Anderson G.G., Footer M.J., et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis Proc Natl Acad Sci USA. 2004;101:1333–1338.

80. Mysorekar I.U., Hultgren S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract Proc Natl Acad Sci USA. 2006;103:14170–14175.

81. Lee P.J., Kuo H.C. High incidence of lower urinary tract dysfunction in women with recurrent urinary tract infections. Low Urin Tract Symptoms. 2020;12:33–40.

82. Hijazi S., Leitsmann C. Clinical significance of video-urodynamic in female recurrent urinary tract infections. Int J Womens Health. 2016;8:31–34.

83. Gadzhieva Z.K. Urodynamic studies in the diagnosis and treatment of urinary disorders. The author’s abstract. diss. Doctor of Medical Sciences, M., 2009. Russian (Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Автореф. дисс. докт. мед. наук. М., 2009).

84. Alyaev Yu.G., Gadzhieva Z.K., Rapoport L.M., Tsarichenko D.G., Kazilov Yu.B. Imperative and obstructive urinary disorders in patients with chronic inflammatory diseases of the urinary tract. Urologiia. 2013;1:7–12. Russian (Аляев Ю.Г., Гаджиева З.К., Рапопорт Л.М., Цариченко Д.Г., Казилов Ю.Б. Императивные и обструктивные нарушения мочеиспускания у пациентов с хроническими воспалительными заболеваниями мочевыводящих путей. Урология. 2013;1:7–12).

85. Isakov Yu.F. Surgical diseases in children. M., 1998. 327. Russian (Исаков Ю.Ф. Хирургические болезни у детей. М., 1998. 327).

86. Wyndaele J.J. Development and evaluation of the management of the neuropathic bladder. Paraplegia 1995;33:305.

87. Gerridzen R.G., Thijssen A.M., Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J. Urol. 1992;147:416.

88. Romikh V.V., Zakharchenko A.V., Borisenko L.Yu., Panteleev V.V., Romikh F.D. Urodynamic disorders of the lower urinary tract and their nature in a group of women suffering from chronic recurrent cystitis. Urological reports. 2017;7(1S):90–91. Russian (Ромих В.В., Захарченко А.В., Борисенко Л.Ю., Пантелеев В.В., Ромих Ф.Д. Нарушения уродинамики нижних мочевых путей и их характер в группе женщин, страдающих хроническим рецидивирующим циститом. Урологические ведомости. 2017;7(1S):90–91).

89. Pushkar D.Yu., Zaitsev A.V. Modern possibilities of immunoprophylaxis of uncomplicated urinary tract infection. Consilium Medicum. 2011;13(7):3–7. Russian (Пушкарь Д.Ю., Зайцев А.В. Современные возможности иммунопрофилактики неосложненной инфекции мочевых путей. Consilium Medicum. 2011;13(7):3–7).

90. Halperin-Walega E. Drug Metab. Dispos. 1988;16(1):130–104.

91. Huber et al. Int J Immunopharmacol. 200;22:1103–1111.

92. Czerwionska-Szaflarska M., Pawlowska M. Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infection. Arch. Immunol. Ther. Exp. 1996;44:195–197.

93. Akhmatova N.K., Khomenkov V.G., Volkova E.V., Akhmatova E.A., Semochkin I.A., Perepanova T.S., Zverev V.V. Bacterial lysates of escherichia coli stimulate production of defensins by peripheral blood neutrophils. Journal of microbiology epidemiology immunobiology. 2016;4:50–55. Russian (Ахматова Н.К., Хоменков В.Г., Волкова Е.В., Ахматова Э.А., Семочкин И.А., Перепанова Т.С., Зверев В.В. Бактериальные лизаты Escherichia coli стимулируют продукцию дефенсинов нейтрофилами периферической крови. Журнал микробиологии, эпидемиологии и иммунобиологии. 2016;4:50–55).

94. Mansfield K.J., Chen Z., Moore K.H., Grundy L. Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms. Front. Physiol. 2022;13:886782. Doi: 10.3389/fphys.2022.886782